Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$44.71M$44.71M+8.2% vs Q2 2018 Net Income-$38.70M-$38.70MN/M vs Q2 2018 EPS Diluted-$0.92-$0.92N/M vs Q2 2018 Operating Income-$36,529,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,111,000N/M Margins · derivedOperating margin-81.7%−29.6 pt vs Q2 2018
Net margin-86.6%−32.5 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 6, 2019 · 37 d after period end